Transgenic and genetically-engineered mutant animals serve as invaluable in vivo models for unraveling the molecular and genetic mechanisms leading to cancer and for evaluating new strategies for treating and preventing cancer. Efficient generation of transgenic and knockout animals requires great technical skill that is acquired only after extensive experience with animal husbandry and breeding, animal surgery, embryo manipulation, and micromanipulation. The Transgenic and Mutant Animal Shared Resource makes transgenic and knockout technologies accessible and affordable to the members of the University of Wisconsin Carbone Cancer Center (UWCCC). It uses the personnel, facilities and equipment from the campus-wide University of Wisconsin Biotechnology Center Transgenic Animal Facility (TAF). Services currently provided by the TAF include: ? Generation of transgenic mice and rats by pronuclear microinjection ? Cryopreservation of mouse and rat embryos ? Generation of knockout mice: generation of targeting vectors, generation of targeted embryonic stem (ES) cell clones, and generation of chimeric mice by injection of ES into host blastocyst ? Strain rederivations and ovarian transplants ? Other miscellaneous molecular biology and embryo services related to transgenic and knockout mouse production ? Consulting and training

Public Health Relevance

Genetically engineered mice and rats have proven to be invaluable models for understanding the molecular biology and molecular pathology of cancer. Through the Wisconsin Biotechnology Center Transgenic Animal Facility, UWCCC members have access to transgenic and mutant mouse models, including animal husbandry and breeding of strains, as well as scientific expertise, which allows investigators to perform cutting edge cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014520-40
Application #
8762772
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-04-01
Budget End
2015-03-31
Support Year
40
Fiscal Year
2014
Total Cost
$122,746
Indirect Cost
$59,443
Name
University of Wisconsin Madison
Department
Type
DUNS #
161202122
City
Madison
State
WI
Country
United States
Zip Code
53715
Goel, Shreya; Ferreira, Carolina A; Chen, Feng et al. (2018) Activatable Hybrid Nanotheranostics for Tetramodal Imaging and Synergistic Photothermal/Photodynamic Therapy. Adv Mater 30:
Wei, Weijun; Ehlerding, Emily B; Lan, Xiaoli et al. (2018) PET and SPECT imaging of melanoma: the state of the art. Eur J Nucl Med Mol Imaging 45:132-150
Yu, Bo; Wei, Hao; He, Qianjun et al. (2018) Efficient Uptake of 177 Lu-Porphyrin-PEG Nanocomplexes by Tumor Mitochondria for Multimodal-Imaging-Guided Combination Therapy. Angew Chem Int Ed Engl 57:218-222
Ehlerding, Emily B; Lacognata, Saige; Jiang, Dawei et al. (2018) Targeting angiogenesis for radioimmunotherapy with a 177Lu-labeled antibody. Eur J Nucl Med Mol Imaging 45:123-131
Shea, Michael P; O'Leary, Kathleen A; Wegner, Kyle A et al. (2018) High collagen density augments mTOR-dependent cancer stem cells in ER?+ mammary carcinomas, and increases mTOR-independent lung metastases. Cancer Lett 433:1-9
Conklin, Matthew W; Gangnon, Ronald E; Sprague, Brian L et al. (2018) Collagen Alignment as a Predictor of Recurrence after Ductal Carcinoma In Situ. Cancer Epidemiol Biomarkers Prev 27:138-145
Ko, Huaising C; Kimple, Randall J (2018) The Resident Individual Development Plan as a Guide for Radiation Oncology Mentorship. Int J Radiat Oncol Biol Phys 101:786-788
McDermott, Andrew J; Tumey, Tyler A; Huang, Mingwei et al. (2018) Inhaled Cryptococcus neoformans elicits allergic airway inflammation independent of Nuclear Factor Kappa B signalling in lung epithelial cells. Immunology 153:513-522
You, Xiaona; Kong, Guangyao; Ranheim, Erik A et al. (2018) Unique dependence on Sos1 in Kras G12D -induced leukemogenesis. Blood 132:2575-2579
Ferreira, Carolina A; Hernandez, Reinier; Yang, Yunan et al. (2018) ImmunoPET of CD146 in a Murine Hindlimb Ischemia Model. Mol Pharm 15:3434-3441

Showing the most recent 10 out of 1528 publications